REG - Smith & Nephew Plc - Director/PDMR Shareholding

Smith & NephewAnnouncement

28/10/2022 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221028:nRSb5155Ea&default-theme=true

RNS Number : 5155E  Smith & Nephew Plc  28 October 2022

SMITH & NEPHEW PLC

 

28 October 2022

 

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE
EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

 

 Reason for the notification
 Initial notification /Amendment                              Initial notification
 Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 Name                                                         Smith & Nephew plc
 LEI                                                          213800ZTMDN8S67S1H61
 Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 Description of the financial instrument, type of instrument  Smith & Nephew plc ordinary shares of USD 0.20 each

 Identification code                                          ISIN: GB0009223206
 Nature of the transaction                                    Purchase of ordinary shares through the Company's Dividend Re-Investment Plan
                                                              following the 2022 interim dividend payment on 26 October 2022.
 Date of Transaction                                          2022 - 10 - 26
 Place of Transaction                                         London Stock Exchange (XLON)

 

 Name                                                             Director / PDMR  Price       Volume     Aggregated information  Total Ordinary Share Holding following the transaction *  Total Ordinary Share Holding as a % of the Company's ISC following the

                                                                                                                                                                                          transaction *
 (Position)
 Bradley Cannon                                                   PDMR             £10.01893   0.00671    N/A Single Transaction  100,240.72690 (including 3,115.77575 in ADS')             0.01142%

 (President, Orthopaedics, Sports Medicine & ENT, Americas)
 Peter Coenen                                                     PDMR             £10.01893   15.6384    N/A Single Transaction  1,229.27131                                               0.00014%

 (President, EMEA)
 Phil Cowdy                                                       PDMR             £10.01893   0.01263    N/A Single Transaction  47,133.99309                                              0.00537%

 (Chief Business Development & Corporate Affairs Officer)
 Myra Eskes                                                       PDMR             £10.01893   350.27072  N/A Single Transaction  27,533.36775                                              0.00314%

 (President APAC and Global Service)
 Simon Fraser                                                     PDMR             £10.01893   353.05042  N/A Single Transaction  27,751.86880                                              0.00316%

 (President AWM and Global Commercial Operations)
 Alison Parkes                                                    PDMR             £10.01893   27.8458    N/A Single Transaction  3,993.17067 (including 712.66244 in ADS')                 0.00045%

 (Chief Compliance Officer)

 

* including those held by Persons Closely Associated with the Director/PDMR.
All figures in these columns are stated to 5 decimal places where applicable.

 

 

Sarah Carne

Deputy Company Secretary

Smith & Nephew plc

 

Tel:  +44 (0)1923 477100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFVIIALTFIF